- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06149286
여포성 림프종 및 변연부 림프종이 있는 참가자에게 레날리도마이드와 결합된 오드로넥스타맙이 안전하고 레날리도마이드와 결합된 리툭시맙보다 효과가 더 좋은지 알아보기 위한 시험 (OLYMPIA-5)
난포성 질환이 있는 재발성/불응성 참가자를 대상으로 레날리도마이드와 레날리도마이드 요법을 병용한 리툭시맙과 항-CD20 x 항-CD3 이중특이적 항체인 오드로넥스타맙(REGN1979)의 효능과 안전성을 비교하기 위한 제3상 공개 라벨 무작위 연구 림프종 및 변연부 림프종(OLYMPIA-5)
This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL) that has come back after treatment (called "relapsed") or did not respond to treatment (called "refractory"). FL and MZL are subtypes of Non-Hodgkin 's Lymphoma (NHL).
This study will be made up of two parts (Part 1 not randomized, Part 2 randomized - controlled).
The aim of Part 1 of the study is to see how safe and tolerable the study drug is when used in combination with lenalidomide, in participants with FL or MZL, and to determine the dose of the study drug to be used in Part 2 of this study. This combination is considered "first-in-human" as it has not been tested as a combination treatment in humans before.
The aim of Part 2, of the study is to assess how well the combination of the study drug and lenalidomide works compared to the combination of rituximab (called "the comparator drug") and lenalidomide. The combination of comparator drug and lenalidomide is the current standard-of-care treatment for relapsed/refractory FL and/or MZL. Standard-of-care means the usual medication expected and used when receiving treatment for a condition.
The study is looking at several other research questions, including:
- What side effects may happen from taking the study drug in combination with lenalidomide
- How much study drug is in the blood at different times
- Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
- The impact from the study drug on quality-of-life and ability to complete routine daily activities
연구 개요
상태
연구 유형
등록 (추정된)
단계
- 3단계
연락처 및 위치
연구 연락처
- 이름: Clinical Trials Administrator
- 전화번호: 844-734-6643
- 이메일: clinicaltrials@regeneron.com
연구 장소
-
-
-
Changhua, 대만, 500-06
- 모병
- Changhua Christian Hospital
-
Changhua, 대만, 50008
- 모병
- Show Chwan Memorial Hospital
-
Kaohsiung City, 대만, 83301
- 모병
- Kaohsiung Chang Gung Memorial Hospital
-
Kaohsiung City, 대만, 80756
- 모병
- Kaohsiung Medical University Hospital
-
New Taipei City, 대만, 23561
- 모병
- Taipei Medical University - Shuang Ho Hospital
-
Tainan, 대만, 701
- 모병
- National Cheng Kung University Hospital
-
Taipei, 대만, 10002
- 모병
- National Taiwan University Hospital
-
Taipei, 대만, 11217
- 모병
- Taipei Veterans General Hospital
-
Taipei, 대만, 11490
- 모병
- Tri-Service General Hospital
-
Taipei, 대만, 116
- 모병
- Taipei Municipal Wan Fang Hospital
-
Taoyuan City, 대만, 333
- 모병
- Chang Gung Memorial Hospital
-
-
Chiayi County
-
Buzi, Chiayi County, 대만, 613
- 모병
- Chang Gung Medical Foundation Chia Yi Branch
-
-
-
-
-
Busan, 대한민국, 49241
- 모병
- Pusan National University Hospital
-
Busan, 대한민국, 47392
- 모병
- Inje University Busan Paik Hospital
-
Daegu, 대한민국, 42415
- 빼는
- Yeyungnam University Medical Center
-
Seoul, 대한민국, 05505
- 모병
- Asan Medical Center
-
Seoul, 대한민국, 06351
- 모병
- Samsung Medical Center
-
Seoul, 대한민국, 3080
- 모병
- Seoul National University Hospital
-
Seoul, 대한민국, 07345
- 모병
- Yeouido St. Marys Hospital
-
Seoul, 대한민국, 03722
- 모병
- Yonsei University Health System
-
Seoul, 대한민국, 137-701
- 모병
- Seoul St Marys Hospital
-
Ulsan, 대한민국, 44033
- 모병
- Ulsan University Hospital
-
-
Gyeonggi-do
-
Suwon, Gyeonggi-do, 대한민국, 16247
- 모병
- St. Vincents Hospital - The Catholic University of Korea
-
-
Jeollabuk
-
Jeonju, Jeollabuk, 대한민국, 54907
- 모병
- Jeonbuk National University Hospital
-
-
Namdong-Gu
-
Incheon, Namdong-Gu, 대한민국, 21565
- 모병
- Gachon University Gil Medical Center
-
-
-
-
-
Halle, 독일, 6120
- 모병
- University Hospital Halle Saale
-
Kiel, 독일, 24116
- 모병
- Stadtisches Krankenhaus Kiel
-
Neuss, 독일, 41462
- 모병
- MVZ fuer Haematologie und Onkologie Rhein-Kreis GmbH
-
-
Baden-Wurttemberg
-
Mutlangen, Baden-Wurttemberg, 독일, 73557
- 모병
- Stauferklinikum
-
Stuttgart, Baden-Wurttemberg, 독일, 70376
- 모병
- Robert-Bosch-Krankenhaus
-
-
Bavaria
-
Munich, Bavaria, 독일, 80337
- 모병
- LMU Klinikum
-
Munich, Bavaria, 독일, 81675
- 모병
- TUM Fakultat fur Medizin - Klinikum Rechts der Isar
-
-
Hesse
-
Frankfurt am Main, Hesse, 독일, 15236
- 모병
- Clinic Frankfurt (Oder)
-
-
North Rhine-Westphalia
-
Essen, North Rhine-Westphalia, 독일, 45122
- 모병
- University Hospital Essen
-
-
Rhineland-Palatinate
-
Mainz, Rhineland-Palatinate, 독일, 55131
- 모병
- Universitatsmedizin der Johannes-Gutenberg Universitat Mainz
-
-
-
-
Johor
-
Johor Bahru, Johor, 말레이시아, 80100
- 모병
- Hospital Sultanah Aminah Jhor Bahru
-
-
Negeri / Wilayah Persekutuan
-
Kuala Lumpur, Negeri / Wilayah Persekutuan, 말레이시아, 50603
- 모병
- University of Malaya Medical Centre
-
-
Sabah
-
Kota Kinabalu, Sabah, 말레이시아, 88586
- 모병
- Hospital Queen Elizabeth
-
-
Selangor
-
Ampang, Selangor, 말레이시아, 68000
- 모병
- Hospital Ampang
-
Subang Jaya, Selangor, 말레이시아, 47500
- 모병
- Subang Jaya Medical Center
-
-
-
-
California
-
Los Angeles, California, 미국, 90095
- 모병
- David Geffen School of Medicine at UCLA
-
-
Florida
-
Plantation, Florida, 미국, 33322
- 모병
- Boca Raton Clinical Research (BRCR) Global
-
-
Indiana
-
Indianapolis, Indiana, 미국, 46202
- 모병
- Indiana University and Comprehensive Cancer Center
-
-
Mississippi
-
Hattiesburg, Mississippi, 미국, 39401
- 모병
- Hattiesburg Clinic
-
-
New Hampshire
-
Lebanon, New Hampshire, 미국, 03756
- 모병
- Dartmouth Cancer Center
-
-
New York
-
Stony Brook, New York, 미국, 11794
- 모병
- Stony Brook University Hospital
-
Westbury, New York, 미국, 11590
- 빼는
- Clinical Research Alliance Inc
-
-
North Carolina
-
Greenville, North Carolina, 미국, 27834
- 모병
- East Carolina University
-
-
Wisconsin
-
Waukesha, Wisconsin, 미국, 53188
- 모병
- Prohealth Care Inc
-
-
-
-
-
Antwerp, 벨기에, 2060
- 모병
- Ziekenhuis Netwerk Antwerpen Stuivenberg
-
Brussels, 벨기에, 1000
- 모병
- Institut Jules Bordet
-
-
Namur
-
Yvoir, Namur, 벨기에, 5530
- 모병
- Centre Hospitalier Universitaire at Universite Catholique de Louvain Namur
-
-
Oost-Vlaanderen
-
Ghent, Oost-Vlaanderen, 벨기에, 9000
- 모병
- Universitair Ziekenhuis (UZ) Gent/ Ghent University Hospital
-
-
West-Vlaanderen
-
Roeselare, West-Vlaanderen, 벨기에, 8800
- 모병
- Algemeen Ziekenhuis AZ Delta
-
-
-
-
-
Rio de Janeiro, 브라질, 20231050
- 모병
- Instituto Nacional de Cancer Jose Alencar Gomes da Silva
-
São Paulo, 브라질, 01321000
- 모병
- A Beneficencia Portuguesa de Sao Paulo, Oncology House
-
São Paulo, 브라질, 01308-050
- 모병
- Hospital Sirio Libanes
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, 브라질, 40285-000
- 모병
- Hospital Sao Rafael
-
-
Federal District
-
Brasília, Federal District, 브라질, 70200-730
- 모병
- Hospital Sirio Libanes Brasilia
-
-
Paraná
-
Cascavel, Paraná, 브라질, 85806-300
- 모병
- Uopeccan Hospital do Cancer de Cascavel
-
Curitiba, Paraná, 브라질, 81520-060
- 모병
- Hospital Erasto Gaertner
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, 브라질, 90035-903
- 모병
- Hospital de Clinicas de Porto Alegre
-
Porto Alegre, Rio Grande do Sul, 브라질, 90110-270
- 모병
- Centro Gaucho Integrado
-
-
São Paulo
-
Jaú, São Paulo, 브라질, 17210-080
- 모병
- Amaral Carvalho Hospital
-
-
-
-
-
Barcelona, 스페인, 08036
- 모병
- Hospital Clinic de Barcelona
-
Barcelona, 스페인, 08035
- 모병
- University Hospital Vall d'Hebron
-
Barcelona, 스페인, 08041
- 모병
- Hospital de la Santa Creu i Sant Pau
-
Granada, 스페인, 18014
- 모병
- Hospital Virgen De Las Nieves De Granada
-
Madrid, 스페인, 28034
- 모병
- Hospital Universitario Ramon y Cajal
-
Madrid, 스페인, 28050
- 모병
- Hospital Universitario HM Sanchinarro
-
Madrid, 스페인, 28040
- 모병
- Fundacion Jimenez Diaz University Hospital
-
Madrid, 스페인, 28041
- 모병
- Hospital Universitario12 de Octubre
-
Salamanca, 스페인, 37007
- 모병
- Hospital Universitario de Salamanca
-
Seville, 스페인, 41013
- 모병
- University Hospital Virgen del Rocio
-
Valencia, 스페인, 46017
- 모병
- University Hospital Doctor Peset
-
Valencia, 스페인, 46009
- 모병
- Instituto Valenciano de Oncologia
-
-
A Coruna
-
Santiago de Compostela, A Coruna, 스페인, 15706
- 모병
- University Hospital of Santiago de Compostela
-
-
Balearic Islands
-
Palma, Balearic Islands, 스페인, 07120
- 모병
- Son Espases University Hospital
-
-
Barcelona
-
L'Hospitalet de Llobregat, Barcelona, 스페인, 08908
- 모병
- Institut Catala d'Oncologia
-
-
Cantabria
-
Santander, Cantabria, 스페인, 39008
- 모병
- Hospital Universitario Marques de Valdecilla
-
-
Madrid
-
Pozuelo de Alarcón, Madrid, 스페인, 28223
- 모병
- Hospital Universitario Quironsalud Madrid
-
-
Principality of Asturias
-
Oviedo, Principality of Asturias, 스페인, 33011
- 모병
- Hospital Universitario Central de Asturias
-
-
-
-
-
Great Yarmouth, 영국, NR31 6LA
- 모병
- James Paget University Hospitals NHS Foundation Trust
-
Romford, 영국, RM7 0AG
- 모병
- Barking, Havering and Redbridge University Hospitals NHS Trust
-
Warwick, 영국, CV34 5BW
- 모병
- South Warwickshire NHS Foundation Trust
-
-
Cornwall
-
Truro, Cornwall, 영국, TR1 3LJ
- 모병
- Royal Cornwall Hospitals NHS Trust, Royal Cornwall Hospital
-
-
Devon
-
Plymouth, Devon, 영국, PL6 8DH
- 모병
- Derriford Hospital and the Royal Eye Infirmary
-
-
Dorset
-
Bournemouth, Dorset, 영국, BH7 7DW
- 모병
- University Hospitals Dorset
-
-
Hampshire
-
Salisbury, Hampshire, 영국, SP6 2ND
- 모병
- Salisbury Foundation Trust
-
-
Middlesex
-
Uxbridge, Middlesex, 영국, UB8 3NN
- 모병
- The Hillingdon Hospital
-
-
Surrey
-
Sutton, Surrey, 영국, SM2 5PT
- 모병
- The Royal Marsden NHS Foundation Trust
-
-
-
-
-
Vienna, 오스트리아, 1090
- 모병
- Medical University Vienna
-
Wels, 오스트리아, 4600
- 모병
- Klinikum Wels-Grieskirchen
-
-
Osterreich
-
Linz, Osterreich, 오스트리아, 4020
- 모병
- Ordensklinikum Linz
-
-
Upper Austria
-
Linz, Upper Austria, 오스트리아, 4020
- 모병
- Kepler University Hospital
-
-
-
-
-
Ashdod, 이스라엘, 7747629
- 모병
- Assuta Ashdod Medical Center
-
Jerusalem, 이스라엘, 91200
- 모병
- Hadassah Medical Center
-
Nahariya, 이스라엘, 2210001
- 모병
- Galilee Medical Center
-
Petah Tikva, 이스라엘, 49100
- 모병
- Rabin Medical Center
-
Ramat Gan, 이스라엘, 5265601
- 모병
- Chaim Sheba Medical Center
-
Tel Aviv, 이스라엘, 64239
- 모병
- The Tel Aviv Sourasky Medical Center
-
Tel Aviv, 이스라엘, 6971028
- 모병
- Assuta Medical Centers
-
-
-
-
-
Bologna, 이탈리아, 40138
- 모병
- University of Bologna Dipartimento di Medicina Specialistica Diagnostica e Sperimentale
-
Brescia, 이탈리아, 25123
- 모병
- Azienda Ospedaliera Spedali Civili di Brescia
-
Milan, 이탈리아, 20141
- 모병
- Istituto Europeo di Oncologia
-
Milan, 이탈리아, 20162
- 모병
- ASST Grande Ospedale Metropolitano Niguarda - Main Address
-
Milan, 이탈리아, 20122
- 모병
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
-
Modena, 이탈리아, 41124
- 모병
- A.O.U. di Modena
-
Naples, 이탈리아, 80131
- 모병
- Federico II University
-
Novara, 이탈리아, 28100
- 모병
- AOU Maggiore della Carita
-
Pavia, 이탈리아, 27100
- 모병
- Fondazione IRCCS Policlinico San Matteo
-
Perugia, 이탈리아, 06132
- 모병
- Azienda Ospedaliera di Perugia
-
Ravenna, 이탈리아, 48121
- 모병
- Ospedale Santa Maria delle Croci
-
Udine, 이탈리아, 33100
- 모병
- Santa Maria della Misericordia
-
-
Forli-Cesena
-
Meldola, Forli-Cesena, 이탈리아, 47014
- 모병
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
-
-
Genova
-
Genoa, Genova, 이탈리아, 16132
- 모병
- Ospedale Policlinico San Martino IRCCS
-
-
Monza E Brianza
-
Monza, Monza E Brianza, 이탈리아, 20900
- 모병
- S Gerardo Hospital
-
-
Piedmont
-
Turin, Piedmont, 이탈리아, 10126
- 모병
- A.O.U. Citta della Salute e della Scienza di Torino
-
-
Pordenone
-
Aviano, Pordenone, 이탈리아, 33081
- 모병
- Centro Di Riferimento Oncologico (CRO), Aviano, National Cancer Institute
-
-
Torino
-
Candiolo, Torino, 이탈리아, 10060
- 모병
- Candiolo Cancer Institute, FPO, IRCCS
-
-
-
-
-
Brno, 체코, 62500
- 모병
- Fakultni Nemocnice Brno
-
Prague, 체코, 10034
- 모병
- University Hospital Kralovske Vinohrady
-
Prague, 체코, 12808
- 모병
- Vseobecna Fakultni Nemocnice V Praze
-
-
East Bohemia
-
Hradec Králové, East Bohemia, 체코, 50005
- 모병
- University Hospital Hradec Kralove
-
-
-
-
-
Bangkok, 태국, 10700
- 모병
- Sriraj Hospital
-
Chiang Mai, 태국, 50200
- 모병
- Chiang Mai University
-
-
Krung Thep Maha Nakhon [Bangko]
-
Bangkok, Krung Thep Maha Nakhon [Bangko], 태국, 10330
- 모병
- Chulalongkorn University
-
-
-
-
-
Istanbul, 터키 (Türkiye), 34093
- 모병
- Istanbul University, Istanbul Medical Faculty
-
Izmir, 터키 (Türkiye), 35340
- 모병
- Dokuz Eylul University
-
Izmir, 터키 (Türkiye), 35100
- 모병
- Ege University
-
Sakarya, 터키 (Türkiye), 54290
- 모병
- Sakarya University Medical Faculty
-
Samsun, 터키 (Türkiye), 55270
- 모병
- Ondokuz Mayıs University
-
Zonguldak, 터키 (Türkiye), 67600
- 모병
- Zonguldak Bulent Ecevit University
-
-
Ankara
-
Mamak, Ankara, 터키 (Türkiye), 06620
- 모병
- Ankara University Faculty of Medicine
-
Yenimahalle, Ankara, 터키 (Türkiye), 06200
- 모병
- Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital
-
-
Central Anatolia
-
Ankara, Central Anatolia, 터키 (Türkiye), 06100
- 모병
- Gazi University
-
-
Mersin
-
Mezitli, Mersin, 터키 (Türkiye), 33200
- 모병
- VM Medical Park Mersin Hospital
-
-
Suleymanpasa
-
Tekirdağ, Suleymanpasa, 터키 (Türkiye), 59100
- 모병
- Tekirdag Namik Kemal University Hospital
-
-
-
-
-
Bydgoszcz, 폴란드, 85-168
- 빼는
- Szpital Uniwersytecki Nr2 Bydgoszcz
-
Katowice, 폴란드, 40-519
- 모병
- Pratia Onkologia Katowice
-
Lodz, 폴란드, 93-513
- 모병
- Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. Mikolaja Kopernika w Lodzi (Copernicus Memorial Hospital)
-
Warsaw, 폴란드, 02-781
- 모병
- Narodowy Instytut Onkologii
-
-
Kuyavian-Pomeranian Voivodeship
-
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 폴란드, 85-048
- 모병
- In-Vivo Sp. z o.o.
-
-
Lower Silesian Voivodeship
-
Wałbrzych, Lower Silesian Voivodeship, 폴란드, 58-309
- 모병
- Specjalistyczny Szpital im A. Sokolowskiego w Walbrzychu
-
Wroclaw, Lower Silesian Voivodeship, 폴란드, 50-367
- 모병
- Uniwersytecki Szpital Kliniczny
-
-
Lublin Voivodeship
-
Lublin, Lublin Voivodeship, 폴란드, 20-090
- 모병
- Uniwersytecki Szpital Kliniczny Nr 4 w Lublinie, Centrum Innowacyjnych Terapii
-
-
Malopolska
-
Krakow, Malopolska, 폴란드, 30-510
- 모병
- Pratia MCM Krakow
-
-
Pomeranian Voivodeship
-
Gdansk, Pomeranian Voivodeship, 폴란드, 80-952
- 모병
- Uniwersyteckie Centrum Kliniczne
-
-
Wielkopolska
-
Poznan, Wielkopolska, 폴란드, 60185
- 완전한
- Pratia Poznan Medical Center
-
Skorzewo, Wielkopolska, 폴란드, 60185
- 모병
- Aidport Sp. z o.o.
-
-
-
-
-
Avignon, 프랑스, 84000
- 모병
- Centre Hospitalier d'Avignon
-
Montpellier, 프랑스, 34290
- 모병
- Centre Hospitalier Universitaire (CHU) Montpellier
-
Paris, 프랑스, 75010
- 모병
- Hopital Saint Louis
-
Paris, 프랑스, 75571
- 모병
- Assistance Publique-Hopitaux de Paris (AP-HP)
-
Saint-Cloud, 프랑스, 92210
- 모병
- Institut Curie
-
-
Bouches Du Rhone
-
Marseille, Bouches Du Rhone, 프랑스, 13009
- 모병
- Institut Paoli-Calmettes
-
-
Brittany Region
-
Rennes, Brittany Region, 프랑스, 35033
- 모병
- CHU de Rennes
-
-
Centre-Val de Loire
-
Tours, Centre-Val de Loire, 프랑스, 37044
- 모병
- Centre Hospitalier Regional Universitaire de Tours
-
-
Gironde
-
Bordeaux, Gironde, 프랑스, 33077
- 모병
- Polyclinique Bordeaux Nord Aquitaine
-
Pessac, Gironde, 프랑스, 33600
- 모병
- Centre Francois Magendie
-
-
Nord
-
Lille, Nord, 프랑스, 5900
- 모병
- Hopital Saint Vincent-de-Paul
-
-
Normandy
-
Rouen, Normandy, 프랑스, 76038
- 모병
- Centre Henri Becquerel
-
-
Pays de la Loire Region
-
Nantes, Pays de la Loire Region, 프랑스, 44093
- 모병
- Nantes University Hospital
-
-
Savoie
-
Chambéry, Savoie, 프랑스, 73000
- 모병
- Centre Hospitalier Metropole Savoie
-
-
Île-de-France Region
-
Argenteuil, Île-de-France Region, 프랑스, 95100
- 모병
- Hopital Victor Dupouy Argenteuil
-
Bobigny, Île-de-France Region, 프랑스, 93000
- 모병
- Avicenne Hospital
-
Villejuif, Île-de-France Region, 프랑스, 94800
- 모병
- Gustave Roussy
-
-
-
-
New South Wales
-
Liverpool, New South Wales, 호주, 2170
- 모병
- Liverpool Hospital
-
Waratah, New South Wales, 호주, 2298
- 모병
- Calvary Mater Newcastle
-
-
Queensland
-
Benowa, Queensland, 호주, 4217
- 모병
- Pindara Private Hospital
-
-
Tasmania
-
Hobart, Tasmania, 호주, 7000
- 모병
- Royal Hobart Hospital
-
-
Victoria
-
East Melbourne, Victoria, 호주, 3121
- 모병
- Epworth Freemasons
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Key Inclusion Criteria:
-
Local histologic confirmation of FL grade 1-3a or MZL (nodal, splenic, or extra nodal MZL) as assessed by the investigator, as described in the protocol.
-
Must have refractory disease or relapsed after at least 1 prior line (with a duration of at least 2 cycles) of systemic chemo-immunotherapy or immunotherapy. Prior systemic therapy should have included at least one anti-Cluster of Differentiation 20 (CD20) monoclonal antibody, and participant should meet indication for treatment, as described in the protocol.
-
Have measurable disease on cross sectional imaging documented by diagnostic Computed Tomography [CT], or Magnetic Resonance Imaging [MRI] imaging, as described in the protocol.
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
-
Adequate hematologic and organ function, as described in the protocol.
-
All study participants must:
- Have an understanding that lenalidomide could have a potential teratogenic risk.
- Agree to abstain from donating blood while taking study drug therapy and for 28 days after discontinuation of lenalidomide.
- Agree not to share study medication with another person.
- Agree to be counseled about pregnancy precautions and risk of fetal exposure associated with lenalidomide.
Key Exclusion Criteria:
- Primary Central Nervous System (CNS) lymphoma or known involvement (either current or prior history of CNS involvement) by non-primary CNS NHL, as described in the protocol.
- Participants with current or past histological evidence of high-grade or diffuse large B-cell lymphoma, or any histology other than FL grade 1-3a or MZL.
- History of or current relevant CNS pathology, as described in the protocol.
- A malignancy other than NHL (inclusion diagnosis) unless the participant is adequately and definitively treated and is cancer free for at least 3 years, with the exception of localized prostate cancer treated with hormone therapy or local radiotherapy (ie, pellets), cervical carcinoma in situ, breast cancer in situ, or nonmelanoma skin cancer that was definitively treated.
- Any other significant active disease or medical condition that could interfere with the conduct of the study or put the participant at significant risk, as described in the protocol.
- Allergy/hypersensitivity to study drugs or excipients. as described in the protocol.
- Active infection as defined in the protocol.
Note: Other protocol-defined Inclusion/Exclusion criteria apply
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Odronextamab+Lenalidomide
In part 1 (safety run-in), participants with R/R indolent lymphoma (FL and MZL), will receive odronextamab in combination with lenalidomide. In part 2, 1:1 randomized participants with R/R FL and MZL, will receive odronextamab in combination with lenalidomide. |
Administered per the protocol
다른 이름들:
Administered per the protocol
다른 이름들:
|
|
실험적: Rituximab+Lenalidomide
In part 2 only, 1:1 randomized participants with R/R FL and ML, will receive rituximab in combination with lenalidomide (R2) followed by lenalidomide monotherapy. |
Administered per the protocol
다른 이름들:
Administered per the protocol
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence of Dose Limiting Toxicities (DLTs) for odronextamab in combination with lenalidomide
기간: Up to 35 days
|
Part 1 |
Up to 35 days
|
|
Incidence of Treatment Emergent Adverse Events (TEAEs) for odronextamab in combination with lenalidomide
기간: Up to 2 years
|
Part 1 |
Up to 2 years
|
|
Severity of TEAEs for odronextamab in combination with lenalidomide
기간: Up to 2 years
|
Part 1 |
Up to 2 years
|
|
Progression-Free Survival (PFS) as assessed by Independent Central Review (ICR)
기간: Up to 5 years
|
Part 2 |
Up to 5 years
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Overall Survival (OS)
기간: Up to 5 years
|
Part 2 |
Up to 5 years
|
|
Time To Next anti-lymphoma Treatment (TTNT)
기간: Up to 5 years
|
Part 2 |
Up to 5 years
|
|
Odronextamab concentrations in serum
기간: Up to 30 months
|
Part 1 and Part 2 |
Up to 30 months
|
|
Incidence of Anti-Drug Antibodies (ADA) to odronextamab
기간: Up to 30 months
|
Part 1 and Part 2 |
Up to 30 months
|
|
Magnitude of ADAs to odronextamab
기간: Up to 30 months
|
Part 1 and Part 2 |
Up to 30 months
|
|
Best Overall Response (BOR) as assessed by investigator review
기간: Up to 30 months
|
Part 1 and Part 2 |
Up to 30 months
|
|
Duration of Response (DOR) as assessed by investigator review
기간: Up to 5 years
|
Part 1 and Part 2 |
Up to 5 years
|
|
PFS as assessed by investigator review
기간: Up to 5 years
|
Part 1 and Part 2 |
Up to 5 years
|
|
Complete Response (CR) as assessed by ICR
기간: Up to 30 months
|
Part 2 |
Up to 30 months
|
|
BOR as assessed by ICR
기간: Up to 30 months
|
Part 2 |
Up to 30 months
|
|
Event Free Survival (EFS) as assessed by ICR
기간: Up to 5 years
|
Part 2 |
Up to 5 years
|
|
EFS as assessed by local investigator review
기간: Up to 5 years
|
Part 2 |
Up to 5 years
|
|
DOR as assessed by ICR
기간: Up to 5 years
|
Part 2 |
Up to 5 years
|
|
Incidence of TEAEs for odronextamab in combination with lenalidomide versus R2
기간: Up to 2 years
|
Part 2 |
Up to 2 years
|
|
Severity of TEAEs for odronextamab in combination with lenalidomide versus R2
기간: Up to 2 years
|
Part 2 |
Up to 2 years
|
|
Overall change in Patient Reported Outcomes (PROs) as measured by scores of European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQC30)
기간: Up to 5 years
|
Part 2 The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a Global Health Status (GHS)/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and GHS/QoL, scores range from 1 = "very poor" to 7 = "excellent" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden. |
Up to 5 years
|
|
Overall change in PROs as measured by scores of Functional Assessment of Cancer Therapy-Lymphoma Subscale (FACT-LymS)
기간: Up to 5 years
|
Part 2 The FACT-Lym Lymphoma Subscale (LymS) includes 15 items to assess NHL-related symptoms and concerns. All questions are answered on a 5-point scale ranging from "not at all" (0) to "very much" (4). Higher scores are associated with a worse quality of life. |
Up to 5 years
|
|
Overall change in PROs as measured by scores of EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L)
기간: Up to 5 years
|
Part 2 The EQ-5D-5L consists of the EQ-5D descriptive system and the EQ Visual Analogue Scale (EQ VAS). The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: "no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems". The EQ VAS records the participant's self-rated health on a vertical visual analogue scale where the endpoints are labeled "Best imaginable health state" and "Worst imaginable health state". |
Up to 5 years
|
|
Change from first assessment in Patient Global Impression on Severity (PGIS)
기간: Up to 5 years
|
Part 2 The PGIS includes a single-item to assess how a patient perceives the overall severity of cancer symptoms over the past 7 days. Patients will choose the response that best describes the severity of their overall cancer symptoms with options on a 5-point scale ranging from 1 (No symptoms) to 4 (Very Severe). |
Up to 5 years
|
|
Change from first assessment in Patient Global Impression on Change (PGIC)
기간: Up to 5 years
|
Part 2 The PGIC item includes a single-item to assess how a patient perceives their overall change in health status since the start of study treatment. Patients will choose from response options on a 7-point scale ranging from 1 (Much Better) to 7 (Much worse); 1- Much Better, 2-Moderately Better, 3-A Little Better, 4-About the Same, 5-A Little Worse, 6-Moderately Worse, 7-Much Worse. |
Up to 5 years
|
|
Change from first assessment in the Global Population item 5 (GP5) items of the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire
기간: Up to 5 years
|
Part 2 A single item (GP5) of the validated FACT-G questionnaire will be used to assess from the participant perspective the overall impact of treatment side-effect. The question item is on a 5-point scale ranging from "not at all" (0) to "very much" (4). |
Up to 5 years
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Clinical Trial Management, Regeneron Pharmaceuticals
간행물 및 유용한 링크
유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 병리학적 과정
- 신생물
- 질병 속성
- 면역계 질환
- 조직학적 유형에 따른 신생물
- 림프계 질환
- 림프 증식 장애
- 면역증식성 장애
- 림프종, 비호지킨
- 림프종, B세포
- 림프종
- 병리학적 상태, 징후 및 증상
- 헴 및 림프병
- 회귀
- 림프종, 여포성
- 림프종, B세포, 변연부
- 아미노산, 펩티드 및 단백질
- 단백질
- 유기 화학 물질
- 이종 사이 클릭 화합물, 1- 링
- 이종 사이 클릭 화합물
- 이종 사이 클릭 화합물, 2- 링
- 이종 사이 클릭 화합물, 융합 링
- 카르 복실 산
- 파이퍼 리딘
- 항체, 모노클로 날
- 항체
- 면역 글로불린
- 면역 단백질
- 혈액 단백질
- 혈청 글로불린
- 글로불린
- 항체, 모노클로 날, 뮤린 유래
- 프탈리 미드
- 프탈산
- 산, 카르 보 사이 클릭
- 파이퍼리돈
- Isoindoles
- 레날리도마이드
- 리툭시맙
기타 연구 ID 번호
- R1979-ONC-22102
- 2022-503092-28-00 (씨티스)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
IPD 공유 기간
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
IPD 공유 액세스 기준
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
- ICF
- ANALYTIC_CODE
- CSR
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .